Kamdar, M., Chavez, J., Olszewski, A., Assouline, S., Lossos, I. S., Diefenbach, C., Modi, D., Sabry, W., Naik, S., Mehta, A., Makadia, S., Pham, S., Peneul, E., Wu, H., Ead, W. S., To, I., Houston, D. J., Batlevi, C. L., Budde, E. (2025). Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study. Blood. https://doi.org/10.1182/blood-2025-3735